Characterisation of synovial fluid and infrapatellar fat pad derived mesenchymal stromal cells: The influence of tissue source and inflammatory stimulus

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Garcia, John ^a,b   Wright, Karina ^a,b   Roberts, Sally ^a,b   Kuiper, Jan Herman ^a,b   Mangham, Chas ^a   Richardson, James ^a,b   Mennan, Claire ^a,b  

^a ROBERT JONES AND AGNES HUNT ORTHOPAEDIC HOSPITAL   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOSE TISSUE; ADULT; AGED; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; FEMALE; HUMAN; INFLAMMATION; MALE; MESENCHYMAL STROMA CELL; MIDDLE AGED; PATELLA; PATHOLOGY; SYNOVIAL FLUID;

ADIPOSE TISSUE; ADULT; AGED; CELL DIFFERENTIATION; CELLS, CULTURED; FEMALE; HUMANS; INFLAMMATION; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; PATELLA; SYNOVIAL FLUID;

EID: 84964322488     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24295     Document Type: Article

References (57)

1. Brittberg, M. et al. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N. Engl. J. Med. 331, 889-895 (1994).
2. Bhosale, A. M., Kuiper, J. H., Johnson, W. E. B., Harrison, P. E. & Richardson, J. B. Midterm to long-term longitudinal outcome of autologous chondrocyte implantation in the knee joint: a multilevel analysis. Am. J. Sports Med. 37, 131S-138S (2009).
3. LaPrade, R. F. & Botker, J. C. Donor-site morbidity after osteochondral autograft transfer procedures. Arthroscopy 20, e69-73 (2004).
4. Matricali, G. A., Dereymaeker, G. P. E. & Luyten, F. P. Donor site morbidity after articular cartilage repair procedures: a review. Acta Orthop. Belg. 76, 669-674 (2010).
5. Paul, J. et al. Donor-site morbidity after osteochondral autologous transplantation for lesions of the talus. J. Bone Joint Surg. Am. 91, 1683-1688 (2009).
6. Jones, E. A. et al. Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis. Arthritis Rheum. 50, 817-827 (2004).
7. Jones, E. A. et al. Synovial fluid mesenchymal stem cells in health and early osteoarthritis: detection and functional evaluation at the single-cell level. Arthritis Rheum. 58, 1731-1740 (2008).
8. Sekiya, I. et al. Human mesenchymal stem cells in synovial fluid increase in the knee with degenerated cartilage and osteoarthritis. J. Orthop. Res. 30, 943-949 (2012).
9. Zhang, S., Muneta, T., Morito, T., Mochizuki, T. & Sekiya, I. Autologous synovial fluid enhances migration of mesenchymal stem cells from synovium of osteoarthritis patients in tissue culture system. J. Orthop. Res. 26, 1413-1418 (2008).
10. Aksu, A. E., Rubin, J. P., Dudas, J. R. & Marra, K. G. Role of gender and anatomical region on induction of osteogenic differentiation of human adipose-derived stem cells. Ann. Plast. Surg. 60, 306-322 (2008).
11. Payne, K. A., Didiano, D. M. & Chu, C. R. Donor sex and age influence the chondrogenic potential of human femoral bone marrow stem cells. Osteoarthritis Cartilage 18, 705-713 (2010).
12. Choudhery, M. S., Badowski, M., Muise, A., Pierce, J. & Harris, D. T. Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation. J. Transl. Med. 12, 8 (2014).
13. Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells . The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-318 (2006).
14. Krampera, M., Galipeau, J., Shi, Y., Tarte, K. & Sensebe, L. Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 15, 1054-1061 (2013).
15. Krampera, M. et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24, 386-398 (2006).
16. Frumento, G. et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196, 459-468 (2002).
17. Nasef, A. et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 84, 231-237 (2007).
18. Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E. & Ringden, O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 31, 890-896 (2003).
19. Li, X. C., Rothstein, D. M. & Sayegh, M. H. Costimulatory pathways in transplantation: challenges and new developments. Immunol. Rev. 229, 271-293 (2009).
20. Deuse, T. et al. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant. 20, 655-667 (2011).
21. English, A. et al. A comparative assessment of cartilage and joint fat pad as a potential source of cells for autologous therapy development in knee osteoarthritis. Rheumatology (Oxford). 46, 1676-1683 (2007).
22. Nigrovic, P. A. & Lee, D. M. Mast cells in inflammatory arthritis. Arthritis Res. Ther. 7, 1-11 (2005).
23. Nakamura, H., Yoshino, S., Kato, T., Tsuruha, J. & Nishioka, K. T-cell mediated inflammatory pathway in osteoarthritis. Osteoarthr. Cartil. 7, 401-402 (1999).
24. de Lange-Brokaar, B. J. E. et al. Synovial inflammation, immune cells and their cytokines in osteoarthritis: A review. Osteoarthr. Cartil. 20, 1484-1499 (2012).
25. Banfi, A. et al. Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy. Exp. Hematol. 28, 707-715 (2000).
26. Wall, M. E., Bernacki, S. H. & Loboa, E. G. Effects of serial passaging on the adipogenic and osteogenic differentiation potential of adipose-derived human mesenchymal stem cells. Tissue Eng. 13, 1291-1298 (2007).
27. Muraglia, A., Cancedda, R. & Quarto, R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J. Cell Sci. 113, 1161-1166 (2000).
28. Lee, D. H. et al. Synovial fluid CD34 - CD44 + CD90 + mesenchymal stem cell levels are associated with the severity of primary knee osteoarthritis. Osteoarthr. Cartil. 20, 106-109 (2012).
29. Wickham, M. Q., Erickson, G. R., Gimble, J. M., Vail, T. P. & Guilak, F. Multipotent stromal cells derived from the infrapatellar fat pad of the knee. Clin. Orthop. Relat. Res. 412, 196-212 (2003).
30. Simmons, D. L., Tan, S., Tenen, D. G., Nicholson-Weller, A. & Seed, B. Monocyte antigen CD14 is a phospholipid anchored membrane protein. Blood 73, 284-289 (1989).
31. Pilz, G. a et al. Human mesenchymal stromal cells express CD14 cross-reactive epitopes. Cytometry. A 79, 635-645 (2011).
32. Klein-Wieringa, I. R. et al. The infrapatellar fat pad of patients with osteoarthritis has an inflammatory phenotype. Ann. Rheum. Dis. 70, 851-857 (2011).
33. Van Landuyt, K. B., Jones, E. a, McGonagle, D., Luyten, F. P. & Lories, R. J. Flow cytometric characterization of freshly isolated and culture expanded human synovial cell populations in patients with chronic arthritis. Arthritis Res. Ther. 12, R15 (2010).
34. Bas, S., Gauthier, B. R., Spenato, U., Stingelin, S. & Gabay, C. CD14 is an acute-phase protein. J. Immunol. 172, 4470-4479 (2004).
35. Bondeson, J., Wainwright, S. D., Lauder, S., Amos, N. & Hughes, C. E. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res. Ther. 8, R187 (2006).
36. Daghestani, H. N., Pieper, C. F. & Kraus, V. B. Soluble macrophage biomarkers indicate inflammatory phenotypes in patients with knee osteoarthritis. Arthritis Rheumatol. (Hoboken, N.J.) 67, 956-65 (2015).
37. Loeser, R. F. Age-Related Changes in the Musculoskeletal System and the Development of Osteoarthritis. Clin. Geriatr. Med. 26, 371-386 (2010).
38. Berenbaum, F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage 21, 16-21 (2013).
39. Greene, M. A. & Loeser, R. F. Aging-related inflammation in osteoarthritis. Osteoarthr. Cartil. 23, 1966-1971 (2015).
40. Bourin, P. et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: A joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International So. Cytotherapy 15, 641-648 (2013).
41. Traktuev, D. O. et al. A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circ. Res. 102, 77-85 (2008).
42. Lopa, S. et al. Donor-matched mesenchymal stem cells from knee infrapatellar and subcutaneous adipose tissue of osteoarthritic donors display differential chondrogenic and osteogenic commitment. Eur. Cell. Mater. 27, 298-311 (2014).
43. Sivanathan, K. N., Gronthos, S., Rojas-Canales, D., Thierry, B. & Coates, P. T. Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation. Stem Cell Rev. 10, 351-375 (2014).
44. Goldring, M. B. & Otero, M. Inflammation in osteoarthritis. Curr. Opin. Rheumatol. 23, 471-478 (2011).
45. Hedbom, E. & Hauselmann, H. J. Molecular aspects of pathogenesis in osteoarthritis: the role of inflammation. Cell. Mol. Life Sci. 59, 45-53 (2002).
46. Epstein, F. H. et al. T-Lymphocyte-Antigen Interactions in Transplant Rejection. N. Engl. J. Med. 322, 510-517 (1990).
47. Sayegh, M. H. & Turka, L. A. The role of T-cell costimulatory activation pathways in transplant rejection. N. Engl. J. Med. 338, 1813-1821 (1998).
48. Rubenhagen, R., Schuttrumpf, J. P., Sturmer, K. M. & Frosch, K.-H. Interleukin-7 levels in synovial fluid increase with age and MMP- 1 levels decrease with progression of osteoarthritis. Acta Orthop. 83, 59-64 (2012).
49. Hancock, W. W. et al. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Natl. Acad. Sci. USA. 93, 13967-13972 (1996).
50. Maillard, N. et al. The immunomodulatory properties of mesenchymal stromal cells isolated from the synovial fluid of human osteoarthritic joints. Osteoarthr. Cartil. 22, S23 (2014).
51. Yamada, H. et al. Preferential accumulation of activated Th1 cells not only in rheumatoid arthritis but also in osteoarthritis joints. J. Rheumatol. 38, 1569-75 (2011).
52. Ryan, J. M., Barry, F., Murphy, J. M. & Mahon, B. P. Interferon-γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin. Exp. Immunol. 149, 353-363 (2007).
53. DelaRosa, O. et al. Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng. Part A 15, 2795-806 (2009).
54. Criado, G., Šimelyte, E., Inglis, J. J., Essex, D. & Williams, R. O. Indoleamine 2,3 dioxygenase-mediated tryptophan catabolism regulates accumulation of Th1/Th17 cells in the joint in collagen-induced arthritis. Arthritis Rheum. 60, 1342-1351 (2009).
55. van Buul, G. M. et al. Mesenchymal stem cells secrete factors that inhibit inflammatory processes in short-term osteoarthritic synovium and cartilage explant culture. Osteoarthr. Cartil. 20, 1186-1196 (2012).
56. Mareschi, K. et al. Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. J. Cell. Biochem. 97, 744-754 (2006).
57. Mackay, A. M. et al. Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng. 4, 415-428 (1998).